1,315
Views
42
CrossRef citations to date
0
Altmetric
Original Article

Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience

, &
Pages 1354-1359 | Received 06 Jul 2017, Accepted 24 Aug 2017, Published online: 08 Sep 2017

References

  • Sandborn WJ, Gasink C, Gao L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;3:1519–1528.
  • Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
  • Kopylov U, Afif W, Cohn A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
  • Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti–tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250.
  • Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
  • Greenup AJ, Rosenfeld G. Development of amyotrophic lateral sclerosis during ustekinumab use for refractory Crohn’s disease. Ann Clin Case Rep. 2017;2:1281.
  • Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
  • Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669.
  • Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohn’s disease successfully treated with ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
  • Sandborn W, Rutgeerts P, Gasink C, et al. Op010 Long term efficacy and safety of ustekinumab for Crohn’s disease: results from IM-UNITI long-term extension through 2 years. J Crohns Colitis. 2017;11:S6.
  • Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. J Crohns Colitis. 2017 [2017 Jun 2]. DOI:10.1093/ecco-jcc/jjx079
  • Moćko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn’s disease: a systematic review and network meta-analysis. Pharmacol Rep. 2016;68:1237–1243.
  • Data on file. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010/EMEA001. Beerse, Belgium: Janssen; 2010.
  • Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17:80.
  • Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191–e192.
  • Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
  • Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.